Pioglitazone

Thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a nuclear transcription factor that regulates adipogenesis, insulin sensitivity, and inflammatory gene expression. Promotes differentiation of small, insulin-sensitive adipocytes while reducing visceral fat inflammation. Also improves hepatic steatosis by redirecting lipid storage from liver and muscle to subcutaneous adipose tissue.

Half-life

3-7 hours (active metabolites 16-24 hours)

Bioavailability

~80% (oral)

Route

oral

Evidence tier

T1 — Multiple RCTs

Optimization pillars

cellular-health · fat-loss

References

3 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

7.5–15 mg/day

Insulin sensitization and NAFLD

moderate

15–30 mg/day

Standard metabolic dosing

aggressive

30–45 mg/day

Full diabetic dosing

Monitoring

fasting-glucose
hba1c
fasting-insulin
homa-ir
alt
ast
lipid-panel
hdl
triglycerides

Contraindications

heart-failure
bladder-cancer-history
active-liver-disease
osteoporosis

References

PMID:16936006Effect of pioglitazone on cardiovascular outcomes in patients with type 2 diabetes: PROactive study — Lancet, 2005
PMID:27931514Pioglitazone for nonalcoholic steatohepatitis: a randomized, controlled trial — Gastroenterology, 2017
PMID:26718975Pharmacotherapy for nonalcoholic fatty liver disease: targeting mechanisms and clinical outcomes — Hepatology, 2016

Notes

Pioglitazone is the insulin sensitizer that fell out of fashion for all the wrong reasons. Rosiglitazone, its cousin in the TZD class, showed cardiovascular risk and the entire class was condemned by association. Pioglitazone actually demonstrated cardiovascular benefit in PROactive and is one of the few drugs that reverses non-alcoholic steatohepatitis on biopsy. The fluid retention and weight gain are real concerns, but they are dose-dependent and manageable at the 15mg range used for metabolic optimization rather than the 45mg used for diabetes. The compound reshapes adipose tissue biology at a fundamental level. That is not a side effect to manage. It is the mechanism to leverage.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Pioglitazone in a protocol matched to you